Alchemab Therapeutics raises €29.3M in British Business Bank's largest-ever life sciences bet

Alchemab Therapeutics, a Cambridge-based clinical-stage biotech founded in 2019 by Dr. Jane Osbourn, has raised €29.3 million (£25 million) in a Series A extension — with the lead investor being the British Business Bank, in what the BBB describes as its largest single life sciences investment to date. Existing investors SV Health Investors, Dementia Discovery Fund, RA Capital, DCVC Bio, Eli Lilly, Lightstone Ventures, Ono Venture Investment, and Camford Partners all participated. The total Series A now stands at approximately £109 million (around €127.8 million).

The Resiliome platform

Alchemab's premise is that the conventional approach to antibody drug discovery — building libraries, screening, iterating — misses the most useful signal. A subset of people who have been exposed to disease never develop symptoms, or recover faster than expected. Their immune systems have done the hard work already. Alchemab's Resiliome platform collects antibody sequences from these disease-resilient individuals and uses AI to mine the patterns, identifying antibodies that have proven protective in the real world.

The platform now holds 500 million antibody sequences. The extension round goes, in part, toward doubling that to one billion — a deliberate data-scale bet that more sequences improve the platform's ability to detect the difference between effective and ineffective protective responses.

The approach is not untested: Alchemab has multiple candidates in its pipeline across neurodegeneration and oncology, with the Dementia Discovery Fund and Eli Lilly among the investor group — a combination that anchors the pipeline in the disease categories where antibody therapeutics have the largest commercial opportunity.

The BBB's largest life sciences bet

The British Business Bank's decision to lead this round — and to do so at a scale it has not matched in life sciences before — is the round's most consequential detail. The BBB is a state-owned development bank; its mandate is to support UK business investment, not to maximise financial return in isolation. Its entry here carries two signals simultaneously: Alchemab's platform is credible enough to attract institutional capital on commercial terms, and the UK government has decided Alchemab is a platform it wants retained domestically.

"This investment provides further validation of the sustainable, long-term potential of our drug discovery platform," Osbourn said, "and will enable us to further accelerate our pipeline of first-in-class antibody therapeutics for conditions with significant unmet need."

The 18-month test

The extension buys Alchemab two things: data scale (the path to one billion sequences) and clinical advancement (pushing additional candidates from discovery into trials). The 18-month test is whether the pipeline produces a Phase II entrant. A single candidate reaching that threshold would validate the platform's ability to translate its disease-resilience hypothesis into clinical evidence — and substantially de-risk the next financing round, which, given the trajectory and the total Series A raised, will likely be a Series B at considerably larger scale.

The risk on the other side: antibody drug discovery is long-cycle, capital-intensive, and littered with platforms that were technically credible and commercially thin. Resiliome's differentiation is the disease-resilience sourcing strategy, not the AI layer alone. Whether that sourcing strategy produces antibodies that perform in clinical trials — not just in sequence analysis — is the one question this extension does not answer.